Simone Rizzetto @SimoneRizzetto88: "📊 PORTFOLIO UPDATE: Iran Peace..."

Italy

📊 PORTFOLIO UPDATE: Iran Peace Deal, Tech Rebounds, and Pharma Catalysts 🚀 One week since the last update and the geopolitical landscape shifted dramatically. The US-Iran peace deal sent shockwaves across global markets,. The relief rally has been immediate and broad. Portfolio riding the momentum. YTD +9.19%, MTD -0.91% but with todays gains we are flat for the month and 10% up YTD. 📌 Macro: The Peace Dividend The Iran conflict had been a persistent source of volatility, driving energy prices up and inflation expectations higher. With the deal in place, the inflation overhang recedes. The ECB had already hiked rates to 2.25% on June 11 in response to the war, but the Fed is expected to hold at its June 17 meeting with high probability. 📌 Pharma: FDA Approvals and Pipeline Progress ➤ $MRK (Merck & Co.): FDA approved the Keytruda-Welireg combination for kidney cancer, first PD-1 plus HIF-2 inhibitor combo. Showed 28% reduction in recurrence risk with 30 analysts maintaining bullish consensus. My position is up over 47% since entry. ➤ $UNH (UnitedHealth): JP Morgan raised PT to $466, Mizuho to $460, BofA upgraded to Buy at $450. Stock hit a 52-week high of $415.97. Board announced 5% dividend increase to $2.32/share and FTC settled Optum Rx insulin pricing concerns. Q1 EPS of $7.23 beat $6.57 estimates with full-year guidance raised above $18.25. 📌 Biotech: Clinical Data and Insider Conviction ➤ $CCCC (C4 Therapeutics Inc): Presented compelling Phase 1 data for cemsidomide at the EHA 2026 Congress on June 12. The drug showed a 53% objective response rate at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients, with a median of 7 prior lines of therapy. Barclays maintains a Buy rating with a $7 price target, and the consensus average target sits at $10.33. ➤ $GH (Guardant Health Inc): Received FDA approval for Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's Hernexeos in HER2-mutant NSCLC. RBC Capital initiated coverage with an Outperform rating and $185 price target, while Goldman Sachs also initiated with a Buy at $165. The stock has been on a tear, up 167% year-over-year. ➤ $SMMT (Summit Therapeutics Inc): Both co-CEOs purchased $50 million each in shares on June 12, roughly $100 million in insider buying. The stock jumped 8.49% on HARMONi-6 Phase III data showing 34% mortality risk reduction in squamous NSCLC. 🚀 Tech: Recovery and AI Infrastructure ➤ $AMD (Advanced Micro Devices Inc): Citi upgraded from Neutral to Buy on June 12, raising the price target from $460 to $575. The company also secured a massive 6-gigawatt GPU deal with Meta for Instinct chips. After the semiconductor sector crash earlier in June, AMD recovered sharply, gaining over 33% in the period. The Meta deal validates AMD's positioning in the AI accelerator market alongside the upcoming MI450 ramp. 📌 My Stance The Iran peace deal is a meaningful de-risking event for global markets. Lower oil prices, reduced geopolitical premium, and returning capital flows to Emerging Markets all support a more constructive backdrop. That said, AI spending remains the dominant fault line in the market. Microsoft had a long losing streak as investors questioned the ROI on massive capex. Meta faces similar scrutiny with reports of a potential $100 billion equity raise to fund AI infrastructure. The narrative is shifting from unlimited AI optimism to demanding evidence of monetization. My healthcare-heavy construction continues to provide diversification benefits. Big pharma delivers regulatory milestones and dividends, biotech offers asymmetric catalysts, and selective tech exposure captures the AI infrastructure trend without overconcentration. The portfolio remains positioned to compound through both calm and turbulent environments. $SPX500 $NSDQ100

Not investment advice. The author may have financial interests in the mentioned instruments.